Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A former employee of Tempus AI, Inc. has sued the Illinois-based company in federal court, alleging that her complaints to human resources about a hostile work environment triggered a months-long ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Tempus AI is a defensible AI-driven healthcare data platform, now trading at a compelling 5.4x EV/sales after a sharp de-rating. TEM's self-reinforcing genomics and data segments drive robust growth, ...

Tempus AI is rated Strong Buy with a $71 12-month price target, reflecting 67% upside after a 60% share price decline. TEM's integrated genomic and clinical data flywheel creates a defensible moat, ...

Tempus AI Inc. (NASDAQ: TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE: MRK) aimed at accelerating AI-driven precision medicine. The stock’s decline comes as ...

Tempus AI (TEM) launched an AI algorithm identifying cancer patients responsive to platinum-based chemotherapy using RNA analysis. Tempus reported preliminary Q4 revenue of $367M, up 83% ...

The opportunity for Tempus AI lies within its data. The company is well connected to many healthcare companies and institutions all over the world, and it can use its vast data set to train advanced ...

Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly ...